TD Cowen has lifted its price target on Insulet Corporation (NASDAQ:PODD) to $379 from $324 while reiterating a Buy rating, ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Presently, Omnipod 5 is FDA-cleared in the United States and C.E. marked for use in those with type 1 diabetes aged two years and older. More on the Omnipod 5 Study ...

Insulet Corp.’s PODD groundbreaking Omnipod 5 Automated Insulin Delivery (“AID”) system (Omnipod 5) received the FDA’s approval for use by type 2 diabetes patients (ages 18 years and above).

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Insulet Corporation (NASDAQ: PODD) (Insulet or the ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations.

A year after his diagnosis, Zach began wearing an Omnipod, which is a small, wearable device that easily delivers insulin. “It’s the first and only pump I've ever been on,” he tells PEOPLE.

The US Food and Drug Administration (FDA) has cleared the Omnipod 5 for use by people aged 18 and older with type 2 diabetes, a first for any automated insulin delivery (AID) system. The Omnipod 5 ...